Comparative Pharmacology
Head-to-head clinical analysis: ASMANEX HFA versus DEXASPORIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASMANEX HFA versus DEXASPORIN.
ASMANEX HFA vs DEXASPORIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mometasone furoate is a corticosteroid that exerts anti-inflammatory effects by inhibiting multiple inflammatory cell types and mediators, including eosinophils, mast cells, macrophages, and lymphocytes, and reducing the release of pro-inflammatory cytokines and chemokines.
Dexasporin is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties. It binds to the glucocorticoid receptor, leading to modulation of gene expression and inhibition of pro-inflammatory mediators such as prostaglandins and leukotrienes.
2 inhalations (100 mcg each) twice daily orally, maximum 400 mcg/day.
1 to 2 mg/kg intramuscular or intravenous every 8 hours.
None Documented
None Documented
The terminal elimination half-life of mometasone furoate following inhalation is approximately 25 hours (range 15–40 hours), reflecting slow absorption from the lungs and prolonged systemic clearance.
3-4 hours (prolonged to 10-15 hours in renal impairment; monitor CrCl <30 mL/min)
Following oral inhalation, the absorbed fraction of mometasone furoate is extensively metabolized in the liver. Excretion is primarily via feces (approximately 74%) and urine (approximately 8%) as metabolites. Biliary excretion contributes to fecal elimination.
Renal excretion (80-90% unchanged), biliary/fecal (10-20%)
Category C
Category C
Corticosteroid, Inhaled
Corticosteroid/Antibiotic Combination